Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

G. Langley, Richard; E. Elewski, Boni; Lebwohl, Mark; Reich, Kristian; Griffiths, C.E.M.; Papp, Kim; Puig, L.; Nakagawa, Hidemi; Spelman, Lynda; Sigurgeirsson, Bárður; Rivas, Enrique; Tsai, Tsen‐Fang; Wasel, Norman; K. Tyring, Stephen; Salko, Thomas; Hampele, Isabelle; Notter, Marianne; Karpov, Alexander; Helou, Silvia; Papavassilis, C.

doi:10.1056/nejmoa1314258

Public

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Published in New England Journal of Medicine • Jul 9, 2014

Authors:

Richard G. Langley

Boni E. Elewski

Mark Lebwohl

Abstract

BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy o...

Subject

Secukinumab

Medicine

Psoriasis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!